Overview

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Status:
NOT_YET_RECRUITING

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

Phase:

PHASE3

Details

Lead Sponsor:

Organon and Co

Treatments:

tapinarof